Sickle cell anemia will lead inherited orphan blood disorders therapeutics sales through 2036 with 38.2% share of the disorder type segment in 2026, driven by expanding clinical protocols and institutional procurement requirements. The market was valued at USD 1.8 billion in 2025 and is expected to be worth USD 4.64 billion by 2036.